WARNINGS O
Concomitant O
use O
of O
benzodiazepiones O
, O
including O
Valium O
, O
and O
opioids O
may O
result O
in O
profound O
sedation B-NonOSE_AE
, O
respiratory B-NonOSE_AE
depression I-NonOSE_AE
, O
coma B-NonOSE_AE
, O
and O
death B-NonOSE_AE
. O

Because O
of O
these O
risks O
, O
reserve O
concomitant O
prescribing O
of O
these O
drugs O
for O
use O
in O
patients O
for O
whom O
alternative O
treatment O
options O
are O
inadequate O
. O

Observational O
studies O
have O
demonstrated O
that O
concomitant O
use O
of O
opioid O
analgesics O
and O
benzodiazepines O
increases O
the O
risk O
of O
drug-related O
mortality B-NonOSE_AE
compared O
to O
use O
of O
opioids O
alone O
. O

If O
a O
decision O
is O
made O
to O
prescribe O
Valium O
concomitantly O
with O
opioids O
, O
prescribe O
the O
lowest O
effective O
dosages O
and O
minimum O
durations O
of O
concomitant O
use O
, O
and O
follow O
patients O
closely O
for O
signs O
and O
symptoms O
of O
respiratory B-NonOSE_AE
depression I-NonOSE_AE
and O
sedation B-NonOSE_AE
. O

In O
patients O
already O
receiving O
an O
opioid O
analgesic O
, O
prescribe O
a O
lower O
initial O
dose O
of O
Valium O
than O
indicated O
in O
the O
absence O
of O
an O
opioid O
and O
titrate O
based O
on O
clinical O
response O
. O

If O
an O
opioid O
is O
initiated O
in O
a O
patient O
already O
taking O
Valium O
, O
prescribe O
a O
lower O
initial O
dose O
of O
the O
opioid O
and O
titrate O
based O
upon O
clinical O
response O
. O

Advise O
both O
patients O
and O
caregivers O
about O
the O
risks O
of O
respiratory B-NonOSE_AE
depression I-NonOSE_AE
and O
sedation B-NonOSE_AE
when O
Valium O
is O
used O
with O
opioids O
. O

Advise O
patients O
not O
to O
drive O
or O
operate O
heavy O
machinery O
until O
the O
effects O
of O
concomitant O
use O
with O
the O
opioid O
have O
been O
determined O
( O
see O
Drug O
Interactions O
) O
. O

Valium O
is O
not O
recommended O
in O
the O
treatment O
of O
psychotic B-Not_AE_Candidate
patients O
and O
should O
not O
be O
employed O
instead O
of O
appropriate O
treatment O
. O

Since O
Valium O
has O
a O
central B-OSE_Labeled_AE
nervous I-OSE_Labeled_AE
system I-OSE_Labeled_AE
depressant I-OSE_Labeled_AE
effect I-OSE_Labeled_AE
, O
patients O
should O
be O
advised O
against O
the O
simultaneous O
ingestion O
of O
alcohol O
and O
other O
CNS-depressant O
drugs O
during O
Valium O
therapy O
. O

As O
with O
other O
agents O
that O
have O
anticonvulsant O
activity O
, O
when O
Valium O
is O
used O
as O
an O
adjunct O
in O
treating O
convulsive B-Not_AE_Candidate
disorders I-Not_AE_Candidate
, O
the O
possibility O
of O
an O
increase O
in O
the O
frequency O
and/or O
severity O
of O
grand B-Not_AE_Candidate
mal I-Not_AE_Candidate
seizures I-Not_AE_Candidate
may O
require O
an O
increase O
in O
the O
dosage O
of O
standard O
anticonvulsant O
medication O
. O

Abrupt O
withdrawal O
of O
Valium O
in O
such O
cases O
may O
also O
be O
associated O
with O
a O
temporary O
increase O
in O
the O
frequency O
and/or O
severity O
of O
seizures B-NonOSE_AE
. O

Pregnancy O
An O
increased O
risk O
of O
congenital B-OSE_Labeled_AE
malformation I-OSE_Labeled_AE
s O
and O
other O
developmental B-OSE_Labeled_AE
abnormalities I-OSE_Labeled_AE
associated O
with O
the O
use O
of O
benzodiazepine O
drugs O
during O
pregnancy B-Not_AE_Candidate
has O
been O
suggested O
. O

There O
may O
also O
be O
non B-OSE_Labeled_AE
- I-OSE_Labeled_AE
teratogenic I-OSE_Labeled_AE
risks I-OSE_Labeled_AE
associated O
with O
the O
use O
of O
benzodiazepines O
during O
pregnancy B-Not_AE_Candidate
. O

There O
have O
been O
reports O
of O
neonatal B-OSE_Labeled_AE
flaccidity I-OSE_Labeled_AE
, O
respiratory O
and O
feeding O
difficulties O
, O
and O
hypothermia O
in O
children O
born O
to O
mothers O
who O
have O
been O
receiving O
benzodiazepines O
late O
in O
pregnancy B-Not_AE_Candidate
. O

In O
addition O
, O
children O
born O
to O
mothers O
receiving O
benzodiazepines O
on O
a O
regular O
basis O
late O
in O
pregnancy B-Not_AE_Candidate
may O
be O
at O
some O
risk O
of O
experiencing O
withdrawal B-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
during O
the O
postnatal I-OSE_Labeled_AE
period O
. O

Diazepam O
has O
been O
shown O
to O
be O
teratogenic B-NonOSE_AE
in O
mice O
and O
hamsters O
when O
given O
orally O
at O
daily O
doses O
of O
100 O
mg/kg O
or O
greater O
( O
approximately O
eight O
times O
the O
maximum O
recommended O
human O
dose O
[ O
MRHD=1 O
mg/kg/day O
] O
or O
greater O
on O
a O
mg/m O
2 O
basis O
) O
. O

Cleft B-NonOSE_AE
palate I-NonOSE_AE
and O
encephalopathy B-NonOSE_AE
are O
the O
most O
common O
and O
consistently O
reported O
malformations B-NonOSE_AE
produced O
in O
these O
species O
by O
administration O
of O
high O
, O
maternally O
toxic O
doses O
of O
diazepam O
during O
organogenesis O
. O

Rodent O
studies O
have O
indicated O
that O
prenatal O
exposure O
to O
diazepam O
doses O
similar O
to O
those O
used O
clinically O
can O
produce O
long-term O
changes B-NonOSE_AE
in I-NonOSE_AE
cellular I-NonOSE_AE
immune I-NonOSE_AE
responses I-NonOSE_AE
, O
brain O
neurochemistry O
, O
and O
behavior O
. O

In O
general O
, O
the O
use O
of O
diazepam O
in O
women O
of O
childbearing O
potential O
, O
and O
more O
specifically O
during O
known O
pregnancy B-Not_AE_Candidate
, O
should O
be O
considered O
only O
when O
the O
clinical O
situation O
warrants O
the O
risk B-OSE_Labeled_AE
to I-OSE_Labeled_AE
the I-OSE_Labeled_AE
fetus I-OSE_Labeled_AE
. O

The O
possibility O
that O
a O
woman O
of O
childbearing O
potential O
may O
be O
pregnant B-NonOSE_AE
at O
the O
time O
of O
institution O
of O
therapy O
should O
be O
considered O
. O

If O
this O
drug O
is O
used O
during O
pregnancy B-Not_AE_Candidate
, O
or O
if O
the O
patient O
becomes O
pregnant B-NonOSE_AE
while O
taking O
this O
drug O
, O
the O
patient O
should O
be O
apprised O
of O
the O
potential O
hazard B-OSE_Labeled_AE
to I-OSE_Labeled_AE
the I-OSE_Labeled_AE
fetus I-OSE_Labeled_AE
. O

Patients O
should O
also O
be O
advised O
that O
if O
they O
become O
pregnant B-NonOSE_AE
during O
therapy O
or O
intend O
to O
become O
pregnant B-NonOSE_AE
they O
should O
communicate O
with O
their O
physician O
about O
the O
desirability O
of O
discontinuing O
the O
drug O
. O

Labor O
and O
Delivery O
Special O
care O
must O
be O
taken O
when O
Valium O
is O
used O
during O
labor O
and O
delivery O
, O
as O
high O
single O
doses O
may O
produce O
irregularities B-OSE_Labeled_AE
in I-OSE_Labeled_AE
the I-OSE_Labeled_AE
fetal I-OSE_Labeled_AE
heart I-OSE_Labeled_AE
rate I-OSE_Labeled_AE
and O
hypotonia B-OSE_Labeled_AE
, O
poor O
sucking O
, O
hypothermia O
, O
and O
moderate O
respiratory O
depression O
in O
the O
neonates I-OSE_Labeled_AE
. O

With O
newborn O
infants O
it O
must O
be O
remembered O
that O
the O
enzyme O
system O
involved O
in O
the O
breakdown O
of O
the O
drug O
is O
not O
yet O
fully O
developed O
( O
especially O
in O
premature B-Not_AE_Candidate
infants I-Not_AE_Candidate
) O
. O

Nursing O
Mothers O
Diazepam O
passes O
into O
breast O
milk O
. O

Breastfeeding O
is O
therefore O
not O
recommended O
in O
patients O
receiving O
Valium O
. O

